1. Volume 58, Issue 1, Pages 1-7 (July 2010)
Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients 
Martin Spahn, Steven Joniau, Paolo Gontero, Steffen Fieuws, Giansilvio Marchioro, Bertrand Tombal, Burkhard Kneitz, Chao-Yu Hsu, Katie Van Der Eeckt, Pia Bader, Detlef Frohneberg, Alessandro Tizzani, Hein Van Poppel 
European Urology 
Volume 58, Issue 1, Pages 1-7 (July 2010)
DOI: /j.eururo
Copyright © 2010 European Association of Urology Terms and Conditions

2. Fig. 1
Estimated survival of the whole study population: (A) free from progression, (B) free from clinical evidence of progressive disease, (C) cancer-related survival, and (D) overall survival.
RP=radical prostatectomy.
European Urology  , 1-7DOI: ( /j.eururo )
Copyright © 2010 European Association of Urology Terms and Conditions

3. Fig. 2
The effect of the considered predictors on (A) biochemical progression-free survival, (B) clinical evidence of progressive disease, (C) prostate cancer–specific mortality, and (D) overall survival. Distinctions are made between patients with only a high preoperative prostate-specific antigen (PSA) (>20), patients that additionally have a clinical stage (cTNM) >2, patients that additionally have a Gleason score >7, and patients that additionally have a cTNM >2 and a Gleason score >7.
RP=radical prostatectomy.
European Urology  , 1-7DOI: ( /j.eururo )
Copyright © 2010 European Association of Urology Terms and Conditions